Sana Biotechnology Announces the Acceptance of Four

SEATTLE, March 14, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that four abstracts, including a late-breaking abstract, highlighting preclinical data from both the hypoimmune and fusogen platforms have been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023 in Orlando, FL.

Late-breaking poster details:

Title:Increased potency of CD8-targeted fusosomes enhances CAR gene delivery to resting primary T cells
Session Title:Late-Breaking Research: Experimental and Molecular Therapeutics 3
Session Date:Wednesday, April 19, 2023
Session Time:9:00 a.m. - 12:30 p.m. ET
Location:Poster Section 35
Abstract Number:LB311


Poster details:

Title:Modulation of resting T cell status to enhance transduction and CAR T expansion following exposure to CD8-targeted fusosomes
Session Category:Experimental and Molecular Therapeutics
Session Title:Gene and Vector-based Therapy
Session Date:Monday, April 17, 2023
Session Time:1:30 p.m. - 5:00 p.m. ET
Location:Poster Section 16
Abstract Number:2734


Title:Development of a novel, fully human anti-CD19 chimeric antigen receptor for in vivo delivery via CD8-targeted fusosome
Session Category:Experimental and Molecular Therapeutics
Session Title:Gene and Vector-based Therapy
Session Date:Monday, April 17, 2023
Session Time:1:30 p.m. - 5:00 p.m. ET
Location:Poster Section 16
Abstract Number:2735


Title:Engineered hypoimmune CAR T cells provide lasting tumor control in immunocompetent allogeneic humanized mice even with re-challenge
Session Category:Immunology
Session Title:CAR T-cell Therapy 2
Session Date:Tuesday, April 18, 2023
Session Time:9:00 a.m. - 12:30 p.m. ET
Location:Poster Section 23
Abstract Number:4091


Full regular abstracts and late-breaking abstract titles are available for viewing via the AACR Online Itinerary Planner located here: https://www.abstractsonline.com/pp8/#!/10828. Late-breaking abstract text will be posted to the AACR Online Itinerary Planner and Meeting App on Friday, April 14, 2023 at 12:00 p.m. ET.

About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester. For more information about Sana Biotechnology, please visit https://sana.com/.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision, progress, and business plans; expectations for the Company’s participation at the 2023 American Association for Cancer Research Annual Meeting; expectations for the Company’s presentations at such meeting, including the content of such presentations; and expectations for the publication of abstracts. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as the economic, market and social disruptions due to the ongoing COVID-19 public health crisis. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Quarterly Report on Form 10-Q dated November 2, 2022. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com


Sana Biotechnology Announces the Acceptance of Four

TIN LIÊN QUAN

Tango Therapeutics to Highlight Preclinical Data on

BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced the acceptance of two oral and two poster...

Mablink Bioscience to Present Promising Preclinical Data

Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR Annual Meeting 2023 In vivo antitumor efficacy with...

Beam Therapeutics to Participate in the 43rd Annual Cowen

CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic...

Lyra Therapeutics Announces Appointment of John Bishop,

WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company...

Molecular Partners to Present at SVB Leerink Global

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...

REE Automotive, Ltd. Announces Date for Fourth Quarter 2022

TEL-AVIV, Israel, March 09, 2023 (GLOBE NEWSWIRE) -- REE Automotive, Ltd. (NASDAQ: REE) (“REE” or the “Company”), an automotive technology company and...

THỦ THUẬT HAY

Hướng dẫn tải ứng dụng Outlook trên iPhone

Ứng dụng Microsoft Outlook có trên cả nền tảng Android và iOS, là ứng dụng email miễn phí giúp bạn hoàn thành công việc mọi lúc mọi nơi. Outlook hiện đã có lượng người dùng lớn trên các thiết bị di động và bài viết

Chuyển ảnh nhanh giữa iPhone với các thiết bị khác không cần cắm dây

Bạn có bao giờ cảm thấy phiền phức khi mỗi lần cần chuyển ảnh từ iPhone sang máy tính hay từ iPhone sang một iPhone khác không?...

Hướng dẫn cách khắc phục các vấn đề liên quan đến thẻ nhớ

Thẻ microSD đôi lúc là cứu cánh, giúp bạn tăng giới hạn lưu trữ trên smartphone. Tuy nhiên, sẽ như thế nào nếu một ngày nào đó chiếc thẻ nhớ của bạn bất ngờ không hoạt động, hay đau đầu hơn khi bạn lỡ xóa đi một vài

Cách cài, chơi Face Dance Challenge, game biểu cảm gương mặt

Lại một sản phẩm khác nữa của người Việt được vinh danh, tựa game Face Dance Challenge với lối chơi cực kỳ hấp dẫn và mới lạ đang làm khuynh đảo bảng xếp hạng ở rất nhiều quốc gia. Còn bạn, bạn đã chơi Face Dance

Đem nút View Image trở lại trên trình duyệt Chrome, Firefox

Hôm nay TCN chia sẻ cho các bạn một extension giúp đem nút View Image trở lại trên trình duyệt Chrome, Firefox. Hãy tải và trải nghiệm nhé.

ĐÁNH GIÁ NHANH

Đánh giá Huawei MateBook 13: Hoàn thiện cao cấp, kích thước gọn, màn hình 3:2 là ưu điểm

Trước đây Huawei đã cho ra mắt chiếc MateBook X Pro với màn hình 13.9 và tỷ lệ 3:2 đặc biệt, nằm trong một thân hình mỏng gọn tại thời điểm gần 3 năm trước cùng cấu hình cũng không phải là yếu. Bây giờ, họ giới thiệu

Đánh giá Vivo V7: Màn hình tràn viền, camera selfie khủng có giúp V7 nổi bật?

So với Vivo V7+, V7 không có bất kì khác biệt nào về ngôn ngữ thiết kế. Máy vẫn trung thành với chất liệu giả kim loại giống như mẫu V7+, cùng các góc cạnh được bo tròn mềm mại kết hợp với tỉ lệ màn hình 18:9 giúp cho

“Mổ xẻ” và khám phá bên trong AirPods 3, có nhiều điểm khác biệt so với AirPods Pro

AirPods 3 đã chính thức được ra mắt sau nhiều ngày mong đợi. Thiết kế mẫu tai nghe mới này được đánh giá tương tự AirPods Pro. Tuy nhiên, khi “mổ bụng” và xem bên trong AirPods 3 thì lại có nhiều điểm không giống bản